Michael Schmertzler, Director at PTC THERAPEUTICS, INC. (PTCT), sold 25,000 shares at $72.86 ($1.8M) on 2026-08-19, disclosed to the SEC on 2026-08-21.
Scheduled sale ($1.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.86 | 5,335 | $389K | 21.5% |
| 2 | $73.67 | 7,165 | $528K | 29.2% |
| 3 | $70.78 | 9,419 | $667K | 36.9% |
| 4 | $71.88 | 2,390 | $172K | 9.5% |
| 5 | $72.92 | 691 | $50K | 2.8% |
| Total | $72.22 avg | 25,000 |
| $1.8M |
| 100% |
| Filing → |
| PTCT | SELL | 2026-09-18 | $1.3M | — | Filing → |
| PTCT | SELL | 2026-09-11 | $1.4M | — | Filing → |
| PTCT | SELL | 2026-08-28 | $1.8M | — | Filing → |